

# Hospital Acquired Infection Treatment-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/H7D6A52E194MEN.html>

Date: May 2018

Pages: 155

Price: US\$ 3,480.00 (Single User License)

ID: H7D6A52E194MEN

## Abstracts

### Report Summary

Hospital Acquired Infection Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hospital Acquired Infection Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Hospital Acquired Infection Treatment 2013-2017, and development forecast 2018-2023

Main market players of Hospital Acquired Infection Treatment in EMEA, with company and product introduction, position in the Hospital Acquired Infection Treatment market  
Market status and development trend of Hospital Acquired Infection Treatment by types and applications

Cost and profit status of Hospital Acquired Infection Treatment, and marketing status

Market growth drivers and challenges

The report segments the EMEA Hospital Acquired Infection Treatment market as:

EMEA Hospital Acquired Infection Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

## Africa

EMEA Hospital Acquired Infection Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Antibacterial  
Antiviral  
Antifungal Treatment  
Antiparasitic  
Antiprotozoal  
Anti-TB Treatment

EMEA Hospital Acquired Infection Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Urinary Tract Infection  
Ventilator-Associated Pneumonia  
Bloodstream Infection  
Surgical Site Infection  
Others

EMEA Hospital Acquired Infection Treatment Market: Players Segment Analysis (Company and Product introduction, Hospital Acquired Infection Treatment Sales Volume, Revenue, Price and Gross Margin):

Abbott Laboratories  
Pfizer Inc.?  
Bayer AG  
Cepheid  
AstraZeneca plc  
F. Hoffmann-La Roche Ltd.  
Johnson & Johnson Services, Inc.  
Merck & Co., Inc  
Cipla Inc.  
GlaxoSmithKline plc  
Aridis Pharmaceuticals, Inc.  
Astellas Pharma Inc.  
Daiichi Sankyo, Inc.

Bristol-Myers Squibb Company  
Eli Lilly and Company

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF HOSPITAL ACQUIRED INFECTION TREATMENT**

- 1.1 Definition of Hospital Acquired Infection Treatment in This Report
- 1.2 Commercial Types of Hospital Acquired Infection Treatment
  - 1.2.1 Antibacterial
  - 1.2.2 Antiviral
  - 1.2.3 Antifungal Treatment
  - 1.2.4 Antiparasitic
  - 1.2.5 Antiprotozoal
  - 1.2.6 Anti-TB Treatment
- 1.3 Downstream Application of Hospital Acquired Infection Treatment
  - 1.3.1 Urinary Tract Infection
  - 1.3.2 Ventilator-Associated Pneumonia
  - 1.3.3 Bloodstream Infection
  - 1.3.4 Surgical Site Infection
  - 1.3.5 Others
- 1.4 Development History of Hospital Acquired Infection Treatment
- 1.5 Market Status and Trend of Hospital Acquired Infection Treatment 2013-2023
  - 1.5.1 Asia Pacific Hospital Acquired Infection Treatment Market Status and Trend 2013-2023
  - 1.5.2 Regional Hospital Acquired Infection Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Hospital Acquired Infection Treatment in Asia Pacific 2013-2017
- 2.2 Consumption Market of Hospital Acquired Infection Treatment in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of Hospital Acquired Infection Treatment in Asia Pacific by Regions
  - 2.2.2 Revenue of Hospital Acquired Infection Treatment in Asia Pacific by Regions
- 2.3 Market Analysis of Hospital Acquired Infection Treatment in Asia Pacific by Regions
  - 2.3.1 Market Analysis of Hospital Acquired Infection Treatment in China 2013-2017
  - 2.3.2 Market Analysis of Hospital Acquired Infection Treatment in Japan 2013-2017
  - 2.3.3 Market Analysis of Hospital Acquired Infection Treatment in Korea 2013-2017
  - 2.3.4 Market Analysis of Hospital Acquired Infection Treatment in India 2013-2017
  - 2.3.5 Market Analysis of Hospital Acquired Infection Treatment in Southeast Asia

2013-2017

2.3.6 Market Analysis of Hospital Acquired Infection Treatment in Australia 2013-2017

2.4 Market Development Forecast of Hospital Acquired Infection Treatment in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Hospital Acquired Infection Treatment in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of Hospital Acquired Infection Treatment by Regions 2018-2023

## **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Hospital Acquired Infection Treatment in Asia Pacific by Types

3.1.2 Revenue of Hospital Acquired Infection Treatment in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Hospital Acquired Infection Treatment in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Hospital Acquired Infection Treatment in Asia Pacific by Downstream Industry

4.2 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in China

4.2.2 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in Japan

4.2.3 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in Korea

4.2.4 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in India

4.2.5 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Hospital Acquired Infection Treatment by Downstream Industry in Australia

4.3 Market Forecast of Hospital Acquired Infection Treatment in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HOSPITAL ACQUIRED INFECTION TREATMENT**

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Hospital Acquired Infection Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 HOSPITAL ACQUIRED INFECTION TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

6.1 Sales Volume of Hospital Acquired Infection Treatment in Asia Pacific by Major Players

6.2 Revenue of Hospital Acquired Infection Treatment in Asia Pacific by Major Players

6.3 Basic Information of Hospital Acquired Infection Treatment by Major Players

6.3.1 Headquarters Location and Established Time of Hospital Acquired Infection Treatment Major Players

6.3.2 Employees and Revenue Level of Hospital Acquired Infection Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 HOSPITAL ACQUIRED INFECTION TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Abbott Laboratories

7.1.1 Company profile

7.1.2 Representative Hospital Acquired Infection Treatment Product

7.1.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.2 Pfizer Inc.?

- 7.2.1 Company profile
- 7.2.2 Representative Hospital Acquired Infection Treatment Product
- 7.2.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Pfizer Inc.?
- 7.3 Bayer AG
  - 7.3.1 Company profile
  - 7.3.2 Representative Hospital Acquired Infection Treatment Product
  - 7.3.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.4 Cepheid
  - 7.4.1 Company profile
  - 7.4.2 Representative Hospital Acquired Infection Treatment Product
  - 7.4.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Cepheid
- 7.5 AstraZeneca plc
  - 7.5.1 Company profile
  - 7.5.2 Representative Hospital Acquired Infection Treatment Product
  - 7.5.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of AstraZeneca plc
- 7.6 F. Hoffmann-La Roche Ltd.
  - 7.6.1 Company profile
  - 7.6.2 Representative Hospital Acquired Infection Treatment Product
  - 7.6.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.7 Johnson & Johnson Services, Inc.
  - 7.7.1 Company profile
  - 7.7.2 Representative Hospital Acquired Infection Treatment Product
  - 7.7.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson Services, Inc.
- 7.8 Merck & Co., Inc
  - 7.8.1 Company profile
  - 7.8.2 Representative Hospital Acquired Infection Treatment Product
  - 7.8.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Merck & Co., Inc
- 7.9 Cipla Inc.
  - 7.9.1 Company profile
  - 7.9.2 Representative Hospital Acquired Infection Treatment Product
  - 7.9.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Cipla Inc.

## 7.10 GlaxoSmithKline plc

### 7.10.1 Company profile

### 7.10.2 Representative Hospital Acquired Infection Treatment Product

### 7.10.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc

## 7.11 Aridis Pharmaceuticals, Inc.

### 7.11.1 Company profile

### 7.11.2 Representative Hospital Acquired Infection Treatment Product

### 7.11.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Aridis Pharmaceuticals, Inc.

## 7.12 Astellas Pharma Inc.

### 7.12.1 Company profile

### 7.12.2 Representative Hospital Acquired Infection Treatment Product

### 7.12.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc.

## 7.13 Daiichi Sankyo, Inc.

### 7.13.1 Company profile

### 7.13.2 Representative Hospital Acquired Infection Treatment Product

### 7.13.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Daiichi Sankyo, Inc.

## 7.14 Bristol-Myers Squibb Company

### 7.14.1 Company profile

### 7.14.2 Representative Hospital Acquired Infection Treatment Product

### 7.14.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

## 7.15 Eli Lilly and Company

### 7.15.1 Company profile

### 7.15.2 Representative Hospital Acquired Infection Treatment Product

### 7.15.3 Hospital Acquired Infection Treatment Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HOSPITAL ACQUIRED INFECTION TREATMENT**

### 8.1 Industry Chain of Hospital Acquired Infection Treatment

### 8.2 Upstream Market and Representative Companies Analysis

### 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HOSPITAL ACQUIRED**



## **INFECTION TREATMENT**

- 9.1 Cost Structure Analysis of Hospital Acquired Infection Treatment
- 9.2 Raw Materials Cost Analysis of Hospital Acquired Infection Treatment
- 9.3 Labor Cost Analysis of Hospital Acquired Infection Treatment
- 9.4 Manufacturing Expenses Analysis of Hospital Acquired Infection Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF HOSPITAL ACQUIRED INFECTION TREATMENT**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Hospital Acquired Infection Treatment-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/H7D6A52E194MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H7D6A52E194MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970